1. |
Itzeu BD, Lolova I, Davidoff M.Immunocytochemical and electromicroscopical data on the differentiation of somatostatincantaining cells in human lage intestin. Anat Anz Jena, 1988; 166(2)∶77.
|
2. |
Smith JP, Solomon TE. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology, 1988; 95(6)∶1541.
|
3. |
Radulovic S, Schally AV, Reile H, et al. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC160) on HT29 human colon cancers in nude mice. Acta Oncol, 1994; 33(6)∶693.
|
4. |
Dy DY, Whitehead RH, Morris DL. SMS 201995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res, 1992; 52(2)∶917.
|
5. |
Singh P, Syle S, Townsend CM. A long acting somatostatin analog (SRIF) (201995) and proglumide (PGL) inhibit the trophic and gastrin receptor (GR) regulatory of effects of pentagastrin (PG) on mouse colon cancer (MC26) cells in vivo. Gastroenterology, 1986; 90(10)∶1636.
|
6. |
黃廣建. 生長抑素在腫瘤診治中的應用. 國外醫學外科學分冊, 1996; 23(2)∶84.
|
7. |
Cascinu S, Ferro EO, Catalano G. A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer, 1995; 71(2)∶97.
|